NASDAQ:SLGL - Nasdaq - IL0011417206 - Common Stock - Currency: USD
SOL-GEL TECHNOLOGIES LTD
NASDAQ:SLGL (2/5/2025, 8:27:23 PM)
After market: 0.723 -0.04 (-4.99%)0.761
+0.05 (+7.17%)
The current stock price of SLGL is 0.761 USD. In the past month the price decreased by -23.88%. In the past year, price decreased by -41.46%.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement ...
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates...
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates...
SLGL stock results show that Sol-Gel Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 82.81 | 799.50B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 29.06 | 380.66B | ||
JNJ | JOHNSON & JOHNSON | 15.48 | 372.43B | ||
MRK | MERCK & CO. INC. | 11.74 | 226.83B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.62 | 219.98B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.86 | 219.54B | ||
PFE | PFIZER INC | 8.5 | 149.84B | ||
SNY | SANOFI-ADR | 13.51 | 134.13B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 51.03 | 121.10B | ||
ZTS | ZOETIS INC | 30.5 | 79.26B | ||
GSK | GSK PLC-SPON ADR | 9.11 | 76.92B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.09 | 42.39B |
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
SOL-GEL TECHNOLOGIES LTD
Golda Meir 7
Ness Ziona 7403648 IL
CEO: Alon Seri-Levy
Employees: 36
Company Website: http://www.sol-gel.com
Investor Relations: http://ir.sol-gel.com
Phone: 97289313433
The current stock price of SLGL is 0.761 USD.
The exchange symbol of SOL-GEL TECHNOLOGIES LTD is SLGL and it is listed on the Nasdaq exchange.
SLGL stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SLGL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SLGL.
SLGL does not pay a dividend.
SLGL does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
The outstanding short interest for SLGL is 2.16% of its float.
ChartMill assigns a technical rating of 3 / 10 to SLGL. When comparing the yearly performance of all stocks, SLGL is a bad performer in the overall market: 68.86% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to SLGL. While SLGL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SLGL reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS decreased by 68.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -35.51% | ||
ROE | -42.73% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to SLGL. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 71.72% and a revenue growth 870.39% for SLGL